Headquartered in Thousand Oaks, CA Fiscal year ends December NASDAQ: AMGN amgen.com
Amgen is a global biotechnology company that discovers, develops, manufactures, and delivers innovative human therapeutics across oncology, cardiovascular disease, inflammation, rare diseases, and obesity. The company's portfolio includes more than two dozen marketed products spanning monoclonal antibodies, bispecific T-cell engager (BiTE) molecules, biosimilars, and small molecules. Key growth franchises include Repatha (cholesterol), EVENITY (osteoporosis), TEZSPIRE (severe asthma, co-developed with AstraZeneca), UPLIZNA (rare autoimmune diseases), BLINCYTO (acute lymphoblastic leukemia), and IMDELLTRA (small cell lung cancer). Amgen is also advancing MariTide, a differentiated antibody-peptide conjugate for obesity and related conditions, through an extensive Phase 3 program. The company operates a large-scale biologics manufacturing network and maintains a deep biosimilar pipeline targeting major reference biologics. Amgen is a component of the Dow Jones Industrial Average and the Nasdaq-100 Index. Updated
The retiring Yum! Brands CEO brings three decades of global consumer scale and pricing discipline to a $242 billion drugmaker that is leaning hard on commercial execution behind obesity and oncology bets. Board additions rarely move a stock, but they signal where management wants outside pressure applied.
Amgen closed at $447.28, a new 52-week high, roughly 55% above last October's $288 level. The $241.8 billion name now sits at the top of its range.
Collecting four figures a month from dividends without ever selling a share sounds straightforward until you price out what it actually costs and see which companies are holding the whole structure together.
Amgen (NASDAQ:AMGN | AMGN Price Prediction) is expected to report third-quarter results on Tuesday, November 3, after the close. The stock is up 41.28% year to date, and management has already warned…
Rich Duprey When a drugmaker's top product loses patent protection, the dividend usually takes the hit. Four pharma giants are each betting on newer drugs to fill the gap, but how close each one…
Treasury yields have turned dividend investing into a minefield, but five mega-caps have quietly raised their payouts through every rate spike, recession, and patent cliff of the past four decades. The question…
A European regulatory endorsement for an oral obesity pill is lifting Eli Lilly (NYSE:LLY | LLY Price Prediction) stock ahead of the rest of the drug group. Eli Lilly stock is up…
Amgen and Merck both yield around 2.3% and have surged this year, but one of them is paying its dividend out of thin air while the other has a cash cushion that…
Retirees watching CD rates scrape bottom and Treasury coupons lock in for a decade have a third option hiding in plain sight inside the Dow Jones Industrial Average, and it requires owning…
Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway. The five names on this list have already replaced their fading blockbusters with something…
Every dividend dollar sitting in a taxable account quietly hands a portion of itself to the IRS year after year, and after two decades that quiet cost compounds into a number most…
Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.
Holding blue-chip Dow dividend payers in a taxable account quietly hands the IRS a cut of every reinvested dollar, year after year, and the compounding cost over two decades is far steeper…
Both Amgen and Merck write quarterly checks and raise them every year, but only one has the portfolio depth to keep growing that payout through the next brutal round of patent expirations.…
Markets are taking a beating as crude oil surges past $100 and Treasury yields hit multi-year highs, setting up a make-or-break inflation report that could seal the Fed's next move. Wall Street…
Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same…
Wall Street returns from summer vacation to a market suddenly bracing for a rate hike, with fresh analyst calls on Intel, Lockheed Martin, Amgen, and SpaceX adding more pressure points to an…
Amgen is a global biotechnology company that discovers, develops, manufactures, and delivers innovative human therapeutics across oncology, cardiovascular disease, inflammation, rare diseases, and obesity.
24/7 Wall St.'s 12-month price target for AMGN is $501.86, rated Buy. The Wall Street consensus target is $397.32. AMGN price prediction →
